Antitrust police raid Sanofi's Hungarian HQ; Glaxo nabs FDA approval for OTC Flonase;

> Hungary's competition watchdog raided Sanofi's ($SNY) domestic headquarters as part of a probe into its wholesaler-selection practices. Report

> The FDA approved an over-the-counter version of Flonase, the allergy-fighting nasal spray from GlaxoSmithKline ($GSK); a launch is planned for next year. Report

> GlaxoSmithKline ($GSK) rolled out its once-weekly Type 2 diabetes treatment Tanzeum (albiglutide), a GLP-1 agonist, in the U.S. Release

> Ranbaxy Laboratories signed up to market Cipher Pharmaceuticals' acne drug Absorica (irotretinoin) in Brazil. Report

> CANbridge Life Sciences inked a marketing partnership with Jazz Pharmaceuticals ($JAZZ) to commercialize the oral mucositis treatment Caphosol in China. Release

> Novo Nordisk ($NVO) signed on to help feed needy families in Egypt during the holy month of Ramadan. Report

> Bayer and Amgen ($AMGN) said their cancer drug Nexavar failed to hit its primary endpoint in another Phase III breast cancer study. Report

And Finally... Want a custom bobblehead for your promo campaign? Amazon now has a 3D printing store. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.